Other Intangible Assets

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Note 5. Other Intangible Assets

Other intangible assets, net were approximately $46,000 at December 31, 2015. Intangible assets with finite useful lives are amortized generally on a straight-line basis over the periods benefited. Intangible assets deemed to have indefinite lives are not amortized but are subject to annual impairment tests. Intangible assets are also reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In December 2014, based on our decision to focus all of our efforts on moving our clinical programs forward, we determined we could not predict the future cash flows from the intangible IPR&D asset related to our Transgenic Rat Program and determined that the intangible asset was impaired and wrote off the approximately $530,000 carrying value of the asset. In the fourth quarter of 2015, based on our annual impairment tests, we determined that certain capitalized patent and license costs were impaired and wrote off approximately $239,000.

The components of our other intangible assets at December 31, 2015 are summarized below:


Other Intangible Asset Class	Cost		Accumulated Amortization			Write Off/ Impairment			Net Carrying Amount		Weighted- Average Amortization Period
Patents		1,243,612		(958,555	)		(239,241	)		45,816		17.0 years

Amortization expense was approximately $72,000 in 2015, $299,000 in 2014, and $269,000 in 2013.

The expected future annual amortization expense for each of the next five years based on current balances of our intangible assets is as follows:


For the year ending December 31:
2016	$	29,529
2017	$	16,287
2018	$	—
2019	$	—
2020	$	—